INO

Announcements

Nothing here yet

Daily updates

• Inovio Pharmaceuticals is developing INO-3107, an investigational DNA immunotherapy for recurrent respiratory papillomatosis associated with HPV types 6 and 11.Oct 10, 2026

FDA designations

Nothing here yet

News

• ApolloBio announces positive Phase 3 topline results for VGX-3100 in cervical dysplasia patientsMay 23, 2026
• INOVIO and Akeso announced a clinical collaboration to advance a novel combination therapy for glioblastomaMar 4, 2026
• FDA accepts INOVIO's BLA for INO-3107 in recurrent respiratory papillomatosisDec 29, 2025
• INOVIO completes rolling BLA submission seeking accelerated approval for INO-3107 as treatment for recurrent respiratory papillomatosis in adultsNov 3, 2025
• INOVIO to begin rolling submission of BLA for INO-3107 for treatment of recurrent respiratory papillomatosis in adultsAug 26, 2025